Bayer Shares Surge on Twin Breakthroughs in Brussels and the Courtroom

Bayer shares jump 4.5% after EU relaxes gene-editing rules and judge keeps glyphosate settlement in Missouri; Supreme Court ruling looms as key catalyst.

Bayer investors enjoyed a rare day of clarity on Thursday, as two long-running sources of uncertainty — one regulatory, one legal — shifted decisively in the company’s favor. The stock climbed 4.5 percent to €37.55, reclaiming ground above its 200-day moving average of €36.17 and notching its highest mark of the month.

The more structural of the two developments came from Brussels. The European Parliament voted on June 18 to relax gene-editing rules, clearing crops developed with techniques such as CRISPR that contain no foreign DNA from the requirement of special labeling. For Bayer’s crop science division, the change removes a bureaucratic hurdle that has slowed the introduction of climate- and pest-resistant varieties. The company and Corteva together control roughly 80 percent of the relevant patents. Consumer advocates have criticised the absence of a mandatory label, and the patent landscape remains contested, but the long-term boost to the agribusiness is unambiguous.

On the litigation front, Bayer secured a procedural win across the Atlantic. Federal judge Henry Edward Autrey on June 17 rejected a motion to shift the proposed glyphosate class-action settlement from St. Louis, Missouri, to California. Keeping the case in Missouri, where most outstanding claims are already consolidated, improves the odds of an orderly resolution. The settlement is valued at up to $7.25 billion, and a final approval hearing is scheduled for July 9 — a date that now looms as the next major catalyst for the equity.

Before that hearing, however, all eyes are on the U.S. Supreme Court. A ruling in the “Durnell” case is due by the end of June, addressing whether a company can be held liable under state law for a product the Environmental Protection Agency has deemed safe. A verdict in Bayer’s favour would effectively erase the vast majority of the roughly 65,000 remaining glyphosate claims; a negative outcome would keep the litigation machine running. UBS analyst Matthew Weston, who rates Bayer a buy with a €52 price target — implying roughly 38 percent upside — hailed the decision to keep the settlement in Missouri as a meaningful step forward.

The stock still trades about 25 percent below its 52-week high of €49.93, a gap that underscores how heavily the legal overhang has weighed on valuations since the Monsanto acquisition. With Brussels reducing regulatory drag and the U.S. judicial calendar offering two potential clearing events in quick succession, the risk-reward dynamic is shifting. For now, the market is betting on resolution — but the binary nature of the Supreme Court ruling means that bet could just as easily turn sour if the justices side with the plaintiffs.